Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Research note

Diagnostic accuracy of SARS-CoV-2 rapid antigen self-tests in asymptomatic individuals in the omicron period: a cross-sectional study

Roderick P. Venekamp¹,¹, a, Ewoud Schuit¹,², a, Lotty Hooft¹,², Irene K. Veldhuijzen³, Wouter van den Bijllaardt⁴,⁵, Suzan D. Pas⁴,⁶, Vivian F. Zwart⁴, Esther B. Lodder⁷, Marloes Hellwich⁸, Marco Koppelman⁹, Richard Molenkamp¹⁰, Constantijn J.H. Wijers¹¹, Irene H. Vroom¹¹, Leonard C. Smeets¹², Carla R.S. Nagel-Imming¹, Wanda G.H. Han³, Susan van den Hof³, Jan A.J.W. Kluytmans¹, Karel G.M. Moons¹,²,*, b

¹) Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands
²) Cochrane Netherlands, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands
³) Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands
⁴) Microvida Laboratory for Medical Microbiology, Amphia Hospital, Breda, the Netherlands
⁵) Department of Infection Control, Amphia Hospital, Breda, the Netherlands
⁶) Microvida Laboratory for Medical Microbiology, Bravis Hospital, Roosendaal, the Netherlands
⁷) Public Health Service West-Brabant, Breda, the Netherlands
⁸) Public Health Service Hart voor Brabant, Tilburg, the Netherlands
⁹) National Screening Laboratory of Sanquin, Sanquin Blood Supply Foundation, Amsterdam, the Netherlands
¹⁰) Department of Viroscience, Erasmus MC, Rotterdam, the Netherlands
¹¹) Public Health Service Rotterdam-Rijnmond, Rotterdam, the Netherlands
¹²) Reinier Haga Medical Diagnostic Center, Delft, the Netherlands

ARTICLE INFO

Article history:
Received 24 August 2022
Received in revised form 2 November 2022
Accepted 8 November 2022
Available online 13 November 2022
Editor: J. M. Hübschen

Keywords:
Asymptomatic individuals
Diagnostic accuracy
Rapid antigen tests
SARS-CoV-2

ABSTRACT

Objectives: To assess the performances of three commonly used antigen rapid diagnostic tests used as self-tests in asymptomatic individuals in the Omicron period.

Methods: We performed a cross-sectional diagnostic test accuracy study in the Omicron period in three public health service COVID-19 test sites in the Netherlands, including 3600 asymptomatic individuals aged ≥ 16 years presenting for SARS-CoV-2 testing for any reason except confirmatory testing after a positive self-test. Participants were sampled for RT-PCR (reference test) and received one self-test (either Acon Flowflex [Flowflex], MP Biomedicals (MPBio), or Siemens-Healthineers CLINITEST [CLINITEST]) to perform unsupervised at home. Diagnostic accuracies of each self-test were calculated.

Results: Overall sensitivities were 27.5% (95% CI, 21.3–34.3%) for Flowflex, 20.9% (13.9–29.4%) for MPBio, and 25.6% (19.1–33.1%) for CLINITEST. After applying a viral load cut-off (≥5.2 log10 SARS-CoV-2 E-gene copies/mL), sensitivities increased to 48.3% (37.6–59.2%), 37.8% (22.5–55.2%), and 40.0% (29.5–51.2%), respectively. Specificities were >99% for all tests in most analyses.

Discussion: The sensitivities of three commonly used SARS-CoV-2 antigen rapid diagnostic tests when used as self-tests in asymptomatic individuals in the Omicron period were very low. Antigen rapid diagnostic test self-testing in asymptomatic individuals may only detect a minority of infections at that point in time. Repeated self-testing in case of a negative self-test is advocated to improve the diagnostic
Introduction

SARS-CoV-2 antigen rapid diagnostic tests (Ag-RDTs) perform adequately when conducted by symptomatic individuals [1,2]. Self-testing by asymptomatic persons, if sufficiently reliable, may also be useful. Individuals could screen themselves before visiting others if they want to minimize posing a risk. Also, it could be used for screening asymptomatic individuals, for example before admission in crowded places. Current evidence suggests that SARS-CoV-2 Ag-RDTs perform sub-optimally in asymptomatic individuals because of lower viral loads in this population [1,3,4]. However, previous studies were small, and either applied professional sampling or were conducted in the pre-Omicron period. We, therefore, studied the accuracy of three Ag-RDTs with unsupervised self-sampling in asymptomatic individuals in the Omicron period, using RT-PCR as the reference standard.

Methods

This study was embedded within the Dutch public testing infrastructure [2]. Formal ethical approval was not required because the study was judged outside the scope of the Dutch Medical Research Involving Human Subjects Act by the METC Utrecht (21-818/C). During the study period (12 January to 30 March 2022), public SARS-CoV-2 testing was conducted by RT-PCR, free-of-charge, for government-approved indications (supplementary material 1 Details on Study Methods). The estimated share of Omicron was >90% of circulating SARS-CoV-2 on 12 January 2022, and >99.5% from 31 January onwards [5-7].

Specimen collection and testing

Individuals aged ≥16 years without symptoms suggestive of SARS-CoV-2 infection were recruited consecutively at three public health service COVID-19 test sites. Trained test site staff took a swab for routine RT-PCR testing [2]. These samples were tested in off-site laboratories on Cobas 6800/8800 platforms. Participants were asked to perform all other study procedures at home within 3 hours of the test site visit: provide informed consent electronically, perform one Ag-RDT self-test (either Acon Flowflex [‘Flowflex’], MP Biomedicals [‘MPBio’], or Siemens-Healthineers CLINITEST [‘CLINITEST’]) using nasal self-sampling according to the manufacturer’s instructions, and complete an online questionnaire (supplementary material 2). Participants interpreted their self-test results visually before receiving their RT-PCR test result from the public health service, and the self-test result was not available to the laboratories conducting the RT-PCR tests. Those with a negative RT-PCR received an online follow-up questionnaire after 10 days (supplementary material 3).

Outcomes and statistical analyses

We performed a complete case analysis because the number of missing values was low (Fig. 1). Confirmatory testers (13% of the study population) were excluded from our primary analyses. Primary outcomes were the diagnostic accuracies of each self-test with RT-PCR test result as the reference standard. Secondary outcomes were diagnostic accuracies stratified by COVID-19 vaccination status, prior SARS-CoV-2 infection, gender, and age. Diagnostic accuracies were also determined after applying a viral load cut-off (≥5.2 log10 SARS-CoV-2 E-gene copies/mL) [8]. Finally, we assessed self-reported infections that may have been missed initially.

Results

Of 4202 participants, 3635 were non-confirmatory testers (Fig. 1). The Ag-RDT self-test and the RT-PCR test result were available for 3600 non-confirmatory testers (99.0%) (Fig. 1). Most participants (83.5%) provided the self-test result within 3 hours of visiting the test site; the median time intervals were 0.96 (interquartile range (IQR), 0.62–1.8), 0.97 (IQR, 0.61–1.9), and 0.69 (IQR,
Ag-RDT self-test accuracies: primary analysis population

Overall sensitivities were 27.5% (21.3–34.3%) for Flowflex, 20.9% (13.9–29.4%) for MPBio, and 25.6% (19.1–33.1%) for CLINITEST (Table 2, Fig. 2). Viral load distributions in RT-PCR–positive individuals show especially false-negative Ag-RDT test results in the lower viral load range (Fig. 3). After applying a viral load cut-off, all stratified sensitivities increased but the 95% CIs still overlapped substantially (Table S2, Fig. S1).

Ag-RDT self-test accuracies: primary versus full analysis population

The largest differences in RT-PCR positivity percentages and sensitivities were between non-confirmatory and confirmatory testers (Table S2, Fig. S2). In the full analysis population, consistently lower sensitivities were found in participants with a prior SARS-CoV-2 infection than in those without a prior infection.

Table 1
Baseline characteristics of the primary analysis population, stratified by a rapid antigen test

| Test site location                                      | Flowflex | MPBio | Clinitest |
|---------------------------------------------------------|----------|-------|-----------|
| Test results available from the reference test and …    |          |       |           |
| Inclusion dates Omicron period (>90% Omicron)           | Jan 12–March 14 | Jan 12–March 29 | Jan 12–March 29 |
| Sample size                                             | N = 1229 | N = 1027 | N = 1344 |
| SARS-CoV-2 infections based on RT-PCR test result, n (%)| 193 (15.7) | 115 (11.2) | 160 (11.9) |
| Age [yrs], mean (SD)                                    | 39 (14) | 38 (15) | 43 (15) |
| Range (min-max)                                         | 16–80 | 16–80 | 16–81 |
| Sex, female, n (%)                                      | 655 (53.3) | 623 (60.7) | 797 (59.4) |
| Self-reported reasons for testing, n (%)a               |          |       |           |
| Symptoms                                                | 40 (3.3) | 42 (4.1) | 43 (3.2) |
| Close contact                                           | 1035 (84.2) | 888 (86.5) | 1213 (90.3) |
| Other reason                                            | 154 (12.5) | 97 (9.4) | 88 (6.5) |
| Vaccination status                                      |          |       |           |
| Not vaccinated                                          | 89 (7.2) | 52 (5.0) | 73 (5.4) |
| Vaccinated with at least one dose, n (%)                | 1140 (92.8) | 975 (95.0) | 1271 (94.6) |
| Number of vaccinations received, n (%)b                 |          |       |           |
| 1                                                       | 68 (6.0) | 69 (7.1) | 80 (6.3) |
| 2                                                       | 361 (31.7) | 413 (42.4) | 496 (39.0) |
| 3                                                       | 710 (62.3) | 493 (50.6) | 686 (54.0) |
| 4                                                       | 1 (0.1) | 0 (0) | 9 (0.7) |
| Unknown                                                 | 0 (0) | 0 (0) | 0 (0) |
| Type of initial vaccination series, n (%)b               |          |       |           |
| Pfizer                                                  | –893 (78.3) | 669 (68.6) | 797 (62.7) |
| Moderna                                                 | 88 (7.7) | 105 (10.8) | 228 (17.9) |
| Astra Zeneca                                            | 67 (5.9) | 116 (11.9) | 149 (11.7) |
| Janssen                                                 | 85 (7.5) | 79 (8.1) | 87 (6.9) |
| Unknown/Other                                           | 7 (0.6) | 6 (0.6) | 10 (0.8) |
| Type of booster vaccine, n (%)c                         |          |       |           |
| Pfizer                                                  | 486 (42.6) | 301 (30.9) | 470 (37.0) |
| Moderna                                                 | 263 (23.1) | 224 (23.0) | 262 (20.6) |
| No booster received                                     | 373 (32.7) | 433 (44.4) | 516 (40.6) |
| Pfizer                                                  | 19 (1.7) | 18 (1.9) | 24 (1.9) |
| Moderna                                                 | 102 (27.7) | 50 (19.9) | 81 (26.0) |
| Astra Zeneca                                            | 6 (3.3) | 5 (1.9) | 10 (3.3) |
| Janssen                                                 | 96 (26.1) | 85 (31.9) | 100 (32.2) |
| Unknown/Other                                           | 1 (0.3) | 1 (0.4) | 0 (0) |
| At least one prior SARS-CoV-2 infection, n (%)           |          |       |           |
| <2 mos ago                                              | 368 (29.9) | 251 (24.5) | 311 (22.2) |
| 2–6 mos ago                                             | 58 (15.8) | 22 (8.8) | 24 (7.7) |
| 6–12 mos ago                                            | 161 (30.2) | 93 (37.1) | 106 (34.1) |
| >12 mos ago                                             | 85 (31.9) | 85 (31.9) | 100 (32.2) |
| Unknown                                                 | 1 (0.3) | 1 (0.4) | 0 (0) |
| Previous experience with using self-tests, n (%)         |          |       |           |
| Performed last self-test, n (%)d                        |          |       |           |
| <7 d ago                                                | 895 (75.5) | 819 (82.6) | 1038 (79.9) |
| 1–4 weeks ago                                           | 188 (15.9) | 115 (11.6) | 162 (12.5) |
| >1 mos ago                                              | 98 (8.3) | 55 (5.6) | 99 (7.6) |
| Unknown                                                 | 4 (0.3) | 2 (0.2) | 1 (0.1) |
| Number of ever-performed self-tests, n (%)e             |          |       |           |
| 1–3                                                     | 147 (12.4) | 146 (14.7) | 220 (16.9) |
| 4–6                                                     | 260 (21.9) | 235 (23.7) | 363 (27.9) |
| >7–10                                                   | 310 (26.2) | 245 (24.7) | 323 (24.9) |
| >10                                                     | 465 (39.2) | 356 (35.9) | 390 (30.0) |

CLINITEST, Siemens-Healthineers CLINITEST Rapid COVID-19 Antigen Test; Flowflex, Acon Labs Flowflex COVID-19 Antigen Home Test; MPBio, MP Biomedicals Rapid SARS-CoV-2 Antigen Test Card; SD, standard deviation.

a All individuals who did not have any symptoms suggestive of SARS-CoV-2 at the actual time of visiting the Covid-19 test site and undergoing the RT-PCR were eligible for study participation. This, however, does not necessarily mean that study participants were asymptomatic at the time of scheduling the test.

b Percentage calculated as the proportion of those vaccinated, or those that had previous experience in performing a self-test, respectively.
Table 2
Diagnostic accuracy parameters for the three Ag-RDTs in the primary analysis population. Values are percentages [95% CI] unless stated otherwise

| N                  | RT-PCR test positivity [%] | Sensitivity [%] [95%CI] | Specificity [%] [95%CI] | PPV [%] [95% CI] | NPV [%] [95% CI] |
|--------------------|---------------------------|------------------------|------------------------|------------------|-----------------|
| **Flowflex**        |                           |                        |                        |                  |                 |
| Primary analysis    | 1229                      | 15.7                   | 27.5 (21.3–34.3)       | 99.8 (99.3–100)  | 96.4 (87.5–99.6)| 88.1 (86.1–89.9)|
|                     | Secondary (stratified)    |                        |                        |                  |                 |
|                   | analyses:                |                        |                        |                  |                 |
| Viral load cut-off | 1221                      | 7.3                    | 48.3 (37.6–59.2)       | 99.2 (98.5–99.6)| 82.7 (69.7–91.8)| 96.1 (94.8–97.1)|
| Vaccinated (at least one): |                        |                        |                        |                  |                 |
| Yes                | 1140                      | 15.1                   | 28.5 (21.9–35.9)       | 99.8 (99.3–100)  | 96.1 (86.5–99.5)| 88.7 (86.7–90.5)|
| No                 | 88                        | 23.9                   | 19.0 (5.4–41.9)        | 100 (94.6–100)  | 100 (39.8–100)  | 79.8 (69.6–87.7)|
| Previous SARS-CoV-2 infection: |                        |                        |                        |                  |                 |
| Yes                | 368                       | 16.3                   | 26.7 (16.1–39.7)       | 99.7 (98.2–100)  | 94.1 (71.3–99.9)| 87.5 (83.5–90.7)|
| No                 | 861                       | 15.4                   | 27.8 (20.4–36.3)       | 99.9 (99.2–100)  | 97.4 (86.2–99.9)| 88.3 (85.9–90.4)|
| **MPBio**          |                           |                        |                        |                  |                 |
| Primary analysis    | 1027                      | 11.2                   | 20.9 (13.9–29.4)       | 99.8 (99.2–100)  | 92.3 (74.9–99.1)| 90.9 (89.0–92.6)|
| Secondary (stratified) analyses: |                        |                        |                        |                  |                 |
| Viral load cut-off | 1026                      | 3.6                    | 37.8 (22.5–55.2)       | 98.8 (97.9–99.4)| 53.8 (33.4–73.4)| 97.7 (96.6–98.5)|
| Vaccinated (at least one): |                        |                        |                        |                  |                 |
| Yes                | 975                       | 10.3                   | 18.0 (11.0–26.9)       | 99.8 (99.2–100)  | 90.0 (68.3–98.8)| 91.4 (89.5–93.1)|
| No                 | 51                        | 29.4                   | 40.0 (16.3–67.7)       | 100 (90.3–100)  | 100 (54.1–100)  | 80.0 (65.4–90.4)|
| Previous SARS-CoV-2 infection: |                        |                        |                        |                  |                 |
| Yes                | 251                       | 14.3                   | 16.7 (6.4–32.8)        | 100 (98.3–100)  | 100 (54.1–100)  | 87.8 (83.0–91.6)|
| No                 | 775                       | 10.2                   | 22.8 (14.1–33.6)       | 99.7 (99.0–100)  | 90.0 (68.3–98.8)| 91.9 (89.7–93.8)|
| **CLINITEST**      |                           |                        |                        |                  |                 |
| Primary analysis    | 1344                      | 11.9                   | 25.6 (19.1–33.1)       | 99.9 (99.5–100)  | 97.6 (87.4–99.9)| 90.9 (89.2–92.4)|
| Secondary (stratified) analyses: |                        |                        |                        |                  |                 |
| Viral load cut-off | 1340                      | 6.3                    | 40.0 (20.5–51.2)       | 99.5 (99.0–99.8)| 85.0 (70.2–94.3)| 96.1 (94.9–97.1)|
| Vaccinated (at least one): |                        |                        |                        |                  |                 |
| Yes                | 1271                      | 12.0                   | 24.8 (18.2–32.5)       | 99.9 (99.5–100)  | 97.4 (86.5–99.9)| 90.7 (88.9–92.2)|
| No                 | 83                        | 8.3                    | 50.0 (11.8–88.2)       | 100 (94.6–100)  | 100 (29.2–100)  | 95.7 (87.8–99.1)|
| Previous SARS-CoV-2 infection: |                        |                        |                        |                  |                 |
| Yes                | 311                       | 9.3                    | 20.7 (8.0–39.7)        | 99.6 (98.0–100)  | 85.7 (42.1–99.6)| 92.4 (89.9–95.1)|
| No                 | 1032                      | 12.7                   | 26.7 (19.4–35.2)       | 100 (99.6–100)  | 100 (90.0–100)  | 90.4 (88.4–92.1)|
| **Sex:**           |                           |                        |                        |                  |                 |
| Female             | 797                       | 11.7                   | 17.2 (10.2–26.4)       | 100 (99.5–100)  | 100 (79.4–100)  | 90.1 (87.8–92.1)|
| Male               | 544                       | 12.1                   | 37.9 (26.2–50.7)       | 99.8 (98.8–100)  | 96.2 (80.4–99.9)| 92.1 (89.4–94.3)|
| **Age [yrs]:**     |                           |                        |                        |                  |                 |
| 16–40              | 568                       | 12.1                   | 24.6 (15.1–36.5)       | 99.8 (99.8–100)  | 94.4 (72.7–99.9)| 90.5 (87.8–92.9)|
| >40                | 775                       | 11.7                   | 26.4 (17.7–36.7)       | 100 (99.5–100)  | 100 (85.8–100)  | 91.1 (88.8–93.0)|

Ag-RDT, antigen rapid diagnostic tests; CLINITEST, Siemens-Healthineers CLINITEST Rapid covid-19 Antigen Test; Flowflex, Acon Labs Flowflex covid-19 Antigen Home Test; MPBio, MP Biomedicals Rapid SARS-CoV-2 Antigen Test Card; NPV, negative predictive value; PPV, positive predictive value.

dSARS-CoV-2 infections based on RT-PCR test results.

b Defined as viral load above which 95% of individuals with a positive RT-PCR test result had a positive viral culture [7] which was 5.2 log10 SARS-CoV-2 E-gene copies/mL.

Fig. 2. Sensitivities with 95% Cs of the Ag-RDT-RT-PCR reference standard test comparisons stratified according to COVID-19 vaccination status, previous infection status, sex, and age. The vertical line indicates the sensitivity of the Ag-RDT in the respective overall study population and the number of positive RT-PCR tests out of the total or subgroup between parentheses. Ag-RDT, antigen rapid diagnostic tests.
Fig. 3. Viral load distribution of reverse transcriptase polymerase chain reaction positive individuals across the three Ag-RDTs, stratified by Ag-RDT self-test result. Ag-RDT, antigen rapid diagnostic tests.
although only reaching statistical significance for Flowflex (Table S2, Fig. S2). Viral load cut-off application resulted in higher sensitivities, but all stratification trends remained similar (Fig. S3).

Positive SARS-CoV-2 tests during 10-day follow-up: primary analysis population

Follow-up information was available for 79.2% (2479/3132) of participants with an initial negative RT-PCR (Table S3). About half (1339/2443; 54.8%) reported having been re-tested within 10 days, with 24.6% of them (329/1339) testing positive.

Discussion

The sensitivities of three Ag-RDT self-tests for detecting the SARS-CoV-2 Omicron variant in asymptomatic individuals using nasal self-sampling were very low, varying between 20.7% and 27.5%, and increasing to only 37.8% to 48.3% after applying a viral load cut-off.

A review of pre-Omicron Ag-RDT evaluations, predominantly using professional sampling, found a pooled sensitivity of 52.5% (95% CI, 43.7–61.1) in asymptomatic individuals [1]. We previously found a sensitivity of 23% for the SD Biosensor self-test based on data from 31 RT-PCR–positive participants in the Delta period [4]. A U.S. study during an Omicron surge found a sensitivity of 52.5% (64/122) for the BinaxNOW Ag-RDT performed by professionals in asymptomatic individuals or those with symptom onset >7 days ago [5].

Sensitivities of Ag-RDTs may be lower in asymptomatic than in symptomatic individuals because of differences in viral load distributions [1,4,9]. Also, retrieving sufficient nasal fluid by self-swatting might be hampered in asymptomatic individuals by the absence of rhinorrhea. The addition of oropharyngeal to nasal self-sampling might increase sensitivities [2,10]; however, it is unlikely that this would have achieved acceptable levels.

Study strengths include the large sample size, real-world context, completeness of data, and blinding of outcome assessment. The study also has some limitations. Firstly, estimates are less precise than anticipated because of the post hoc exclusion of asymptomatic confirmatory testers. Secondly, the viral load calculations were based on standard curves generated in a previous study and should therefore be considered the best estimates [8]. We used a cut-off above which 95% of people with a positive RT-PCR test result had a positive virus culture in that previous study [8]. Those experiments were performed when Alpha dominated and in a largely unvaccinated population.

We conclude that SARS-CoV-2 self-testing has limited value for asymptomatic individuals wishing to protect vulnerable persons and may even lead to a false sense of security. One should be aware of this, and better informed about other prevention options, such as physical distancing or mask use, on the other hand, all evaluated self-tests were highly specific. Therefore, self-testing regardless of symptoms is useful in other public health contexts because every positive test captured reduces the number of subsequent exposures. The high SARS-CoV-2 infection rate within 10 days of a negative RT-PCR test that we found in our study emphasizes the importance of re-testing over time, especially when symptoms develop, to reduce missed infections as much as possible.

Author contributions

KGMM initiated the study. ES, RPV, LH, IKV, WvdB, SDP, EL, MH, RM, CW, IV, CRSN-I, SvdH, JAWK, JHHMvdW, and KGMM designed the study. ES, RPV, CRSN-I, and KGMM coordinated the study. WvdB, SDP, VFZ, LS, and MK were responsible for laboratory analyses and data processing. ES, RPV, and KGMM verified the underlying data. ES performed the statistical analysis and verified the underlying data in close collaboration with RPV and KGMM. RPV, ES, JHHMvdW, and KGMM drafted the first version of the manuscript. All authors critically read the manuscript and provided feedback. All authors approved the submission of the current version of the manuscript. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

Transparency declaration

The authors declare that they have no conflicts of interest.

Funding

This research was supported from the Dutch Ministry of Health, Welfare, and Sport. The funder had no role in the design, collection, analysis, and interpretation of data; writing and decision to submit the paper for publication.

Acknowledgements

We thank the participants, and study staff at the participating public health service test sites, participating laboratories, the University Medical Center Utrecht, and RIVM for their contributions to the study. A special thanks to Esther Stiefelhagen, Renskje Beekes, Sophie Neeleman, Eveline Westergaard, Roel Ensing, Wendy Mouthaan, and Timo Boelsums. Written permission was obtained from all five of them to list their names. ES, RB, SN, RE, WH, LB, and TB did not receive any compensation for their contributions.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.cmi.2022.11.004.

References

[1] Brümmer LE, Katzenschlager S, Gaedert M, Erdmann C, Schmitz S, Bota M, et al. Accuracy of novel antigen rapid diagnostics for SARS-CoV-2: a living systematic review and meta-analysis. PLoS Med 2021;18:e1003735. https://doi.org/10.1371/journal.pmed.1003735.
[2] Schuit E, Venekamp RP, Hooft L, Veldhuijzen IK, van den Bijlaardt W, Pas SD, et al. Diagnostic accuracy of covid-19 rapid antigen tests with unsupervised self-sampling in people with symptoms in the omicron period: cross sectional study. BMJ 2022;378:e071215. https://doi.org/10.1136/bmj-2022-071215.
[3] Boehme C, Hannay E, Sampath R. SARS-CoV-2 testing for public health use: core principles and considerations for defined use settings. Lancet Glob Health 2021;9:e247–9. https://doi.org/10.1016/S2214-109X(21)00006-1.
[4] Schuit E, Venekamp RP, Veldhuijzen IK, van den Bijlaardt W, Pas SD, Stohr JMJ, et al. Accuracy and usability of saliva and nasal rapid antigen self-testing for detection of SARS-CoV-2 infection in the general population: a head-to-head comparison. BMC Med 2022;20:406. https://doi.org/10.1186/s12916-022-02603-x.
[5] Rijksoverheid Variants of the coronavirus. 2021 [updated 2 December 2021]. Available from: https://coronavirus-dashboard.rijksoverheid.nl/landelijk/variaten. [Accessed 22 August 2022].
[6] RIVM Centrum Infectieziektebestrijding. Variants of the corona virus SARS-CoV-2 [Dutch]. 2021 [updated 30 November 2021]. Available from, https://www.rivm.nl/coronavirus-cov-19/variaat/varianten. [Accessed 22 August 2022].
[7] RIVM Centrum Infectieziektebestrijding. Epidemiologische situatie van SARS-CoV-2 in Nederland [Dutch]. 2021 [updated 28 September 2021]. Available from, https://www.rivm.nl/sites/default/files/2021-09/COVID-19_Website-rapport_wekelijks_20210928_1146_final.pdf.
[8] Schuit E, Veldhuijzen IK, Venekamp RP, van den Bijlaardt W, Pas SD, Lodder EB, et al. Diagnostic accuracy of rapid antigen tests in asymptomatic
Schrom J, Marquez C, Pilarowski G, Wang CY, Mitchell A, Puccinelli R, et al. Comparison of SARS-CoV-2 reverse transcriptase polymerase chain reaction and BinaxNOW rapid antigen tests at a community site during an Omicron surge: a cross-sectional study. Ann Intern Med 2022;175:682–90. https://doi.org/10.7326/M22-0202.

Goodall BL, LeBlanc JJ, Hatchette TF, Barrett L, Patriquin G. Investigating the sensitivity of nasal or throat swabs: combination of both swabs increases the sensitivity of SARS-CoV-2 rapid antigen tests. Microbiol Spectr 2022;10:e0021722. https://doi.org/10.1128/spectrum.00217-22.